Data Dive: Unpacking Datopotomab Deruxtecan and Its Recent FDA Approval

Podcast | English | 2025 | 45 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Jacob Sands to discuss the recent approval of datopotamab deruxtecan for locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

Podcast Host:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Jacob Sands, MD, Assistant Professor of Medicine, Harvard Medical School, Lowe Cancer Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA